Cantor Fitzgerald Starts Evogene Ltd (EVGN) at Overweight

November 30, 2020 4:04 PM EST
Get Alerts EVGN Hot Sheet
Price: $3.04 +5.92%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Evogene Ltd (NASDAQ: EVGN) with a Overweight rating and a price target of $9.00.

The analyst comments "Evogene has a Computational Predictive Biology (CPB) platform that incorporates deep scientific understanding, big data, and artificial intelligence (AI) with the goal of discovering and developing novel life science-based products. These products are developed through five subsidiaries under Evogene: AgPlenus (ag-chemicals), Biomica (human-microbiome based therapies), Canonic (medical cannabis), Casterra (ag-solutions for castor), and Lavie Bio (ag-biologicals). Core components focus on MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements). We think the innovation from Israel is highly underappreciated and view Evogene as an under-the-radar company. In our view, additional program execution across Evogene's subsidiaries in 2021 could bring additional interest to the story, as some programs near potential commercialization."

For an analyst ratings summary and ratings history on Evogene Ltd click here. For more ratings news on Evogene Ltd click here.

Shares of Evogene Ltd closed at $2.96 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

Cantor Fitzgerald